Do analysts prefer SLXN or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SLXN or REVB?

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A

Is SLXN or REVB more profitable?

Revelation Biosciences' return on equity of -107.65% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Revelation Biosciences N/A -107.65% -87.98%

Do analysts prefer LABT or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LABT or SLXN?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A

Is LABT or SLXN more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Silexion Therapeutics N/A -516.86% -176.68%

Does the media prefer LABT or SLXN?

In the previous week, Silexion Therapeutics had 1 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Silexion Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SXTP or SLXN?

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, suggesting a potential upside of 793.55%. Given 60 Degrees Pharmaceuticals' higher probable upside, research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SLXN or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SLXN or CUPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, SLXN or CUPR?

Cuprina Holdings (Cayman) has higher revenue and earnings than Silexion Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Cuprina Holdings (Cayman) $40K 75.90 -$3.63M N/A N/A

Is SLXN or CUPR more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Cuprina Holdings (Cayman) N/A N/A N/A

Does the media refer more to SLXN or CUPR?

In the previous week, Silexion Therapeutics had 1 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 0.59 beat Silexion Therapeutics' score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cuprina Holdings (Cayman) 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silexion Therapeutics (SLXN) Competitors

$2.52 +0.01 (+0.40%)

Closing price 07/22/2026 04:00 PM Eastern

Extended Trading

$2.61 +0.09 (+3.57%)

As of 05:48 AM Eastern

Compare

SLXN vs. REVB, LABT, SXTP, CAPS, and CUPR

Should you buy Silexion Therapeutics stock or one of its competitors? MarketBeat compares Silexion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silexion Therapeutics include Revelation Biosciences (REVB), Lakewood-Amedex Biotherapeutics (LABT), 60 Degrees Pharmaceuticals (SXTP), Capstone Therapeutics (CAPS), and Cuprina Holdings (Cayman) (CUPR). These companies are all part of the "pharmaceutical products" industry.

How does Silexion Therapeutics compare to Revelation Biosciences?

Silexion Therapeutics (NASDAQ:SLXN) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Revelation Biosciences' return on equity of -107.65% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Revelation Biosciences	N/A	-107.65%	-87.98%

Silexion Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for Revelation Biosciences. Silexion Therapeutics' average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Revelation Biosciences	Neutral

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Revelation Biosciences beats Silexion Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Silexion Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.0% of Silexion Therapeutics shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Silexion Therapeutics	N/A	-516.86%	-176.68%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Silexion Therapeutics beats Lakewood-Amedex Biotherapeutics on 6 of the 9 factors compared between the two stocks.

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, suggesting a potential upside of 793.55%. Given 60 Degrees Pharmaceuticals' higher probable upside, research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Silexion Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.92	-$7.36M	-$8.92	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

Silexion Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Silexion Therapeutics	N/A	-516.86%	-176.68%

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Silexion Therapeutics had 2 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Silexion Therapeutics'average media sentiment score.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Neutral
Silexion Therapeutics	Neutral

60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Silexion Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Silexion Therapeutics compare to Capstone Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Silexion Therapeutics has higher earnings, but lower revenue than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A

Silexion Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 4.1% of Silexion Therapeutics shares are owned by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Silexion Therapeutics had 2 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for Capstone Therapeutics. Silexion Therapeutics' average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Capstone Therapeutics	Neutral

Silexion Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Summary

Silexion Therapeutics beats Capstone Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to Cuprina Holdings (Cayman)?

Silexion Therapeutics (NASDAQ:SLXN) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Cuprina Holdings (Cayman) has higher revenue and earnings than Silexion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Cuprina Holdings (Cayman)	$40K	75.90	-$3.63M	N/A	N/A

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.0% of Silexion Therapeutics shares are owned by institutional investors. 4.1% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 0.59 beat Silexion Therapeutics' score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silexion Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, suggesting that its stock price is 210% less volatile than the broader market.

Summary

Silexion Therapeutics beats Cuprina Holdings (Cayman) on 6 of the 11 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05M	$3.68B	$7.01B	$12.68B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-0.03	21.19	26.83	23.95
Price / Sales	N/A	306.01	576.15	115.11
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	0.30	8.00	10.56	6.16
Net Income	-$11.91M	$23.81M	$3.60B	$331.73M
7 Day Performance	-9.35%	-1.22%	-1.35%	-0.92%
1 Month Performance	-7.01%	-1.36%	-0.29%	-2.23%
1 Year Performance	-98.09%	34.77%	18.96%	14.79%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	0.8168 of 5 stars	$2.52 +0.4%	N/A	-98.0%	$1.05M	N/A	N/A	N/A
REVB Revelation Biosciences	0.9907 of 5 stars	$1.09 +4.3%	N/A	-90.6%	$4.23M	N/A	N/A	10
LABT Lakewood-Amedex Biotherapeutics	0.5095 of 5 stars	$2.36 -7.6%	N/A	N/A	$4.14M	N/A	N/A	5	News Coverage Analyst Forecast Gap Down High Trading Volume
SXTP 60 Degrees Pharmaceuticals	3.4174 of 5 stars	$1.49 +2.2%	$13.85 +828.3%	-70.9%	$3.97M	$1.41M	N/A	3	Gap Up
CAPS Capstone Therapeutics	0.3817 of 5 stars	$0.26 +1.6%	N/A	-85.1%	$3.91M	$51.62M	N/A	38	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. REVB, LABT, SXTP, CAPS, and CUPR

How does Silexion Therapeutics compare to Revelation Biosciences?

Summary

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does Silexion Therapeutics compare to Capstone Therapeutics?

Summary

How does Silexion Therapeutics compare to Cuprina Holdings (Cayman)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. REVB, LABT, SXTP, CAPS, and CUPR

How does Silexion Therapeutics compare to Revelation Biosciences?

Is SLXN or REVB more profitable?

Which has more risk & volatility, SLXN or REVB?

Does the media prefer SLXN or REVB?

Which has higher valuation & earnings, SLXN or REVB?

Do analysts prefer SLXN or REVB?

Do insiders and institutionals believe in SLXN or REVB?

Summary

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Does the media prefer LABT or SLXN?

Do insiders and institutionals hold more shares of LABT or SLXN?

Which has better earnings and valuation, LABT or SLXN?

Is LABT or SLXN more profitable?

Do analysts prefer LABT or SLXN?

Summary

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

Do analysts prefer SXTP or SLXN?

Which has higher valuation and earnings, SXTP or SLXN?

Is SXTP or SLXN more profitable?

Do institutionals & insiders hold more shares of SXTP or SLXN?

Does the media favor SXTP or SLXN?

Which has more volatility & risk, SXTP or SLXN?

Summary

How does Silexion Therapeutics compare to Capstone Therapeutics?

Which has stronger earnings and valuation, SLXN or CAPS?

Is SLXN or CAPS more profitable?

Do institutionals and insiders believe in SLXN or CAPS?

Do analysts recommend SLXN or CAPS?

Does the media refer more to SLXN or CAPS?

Which has more risk & volatility, SLXN or CAPS?

Summary

How does Silexion Therapeutics compare to Cuprina Holdings (Cayman)?

Which has better valuation and earnings, SLXN or CUPR?

Is SLXN or CUPR more profitable?

Do analysts recommend SLXN or CUPR?

Do insiders and institutionals believe in SLXN or CUPR?

Does the media refer more to SLXN or CUPR?

Which has more volatility & risk, SLXN or CUPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools